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background: The EVEREST II High Risk Registry (HRR) enrolled 78 patients with severe mitral regurgitation (MR) who were too high risk for mitral 
valve (MV) surgery. As of November 2013, all patients completed 5 year follow-up. Results through 1 year have been published, and final outcomes 
through 5 years will be presented.
Methods: EVEREST II HRR is a prospective, multi-center trial which enrolled patients with 3+ or 4+ MR considered at high risk of surgical mortality 
as predicted by a STS operative mortality risk of ≥12%, or surgeon assessment based on pre-specified high surgical risk factors. Outcome measures 
included mortality, NYHA class, quality of life measures, hospitalizations for CHF, and echocardiographic measurements by an independent core lab.
results: Mean age was 77 ±10 years; baseline LVEF was 54%. Functional MR (FMR) was present in 59% and degenerative MR (DMR) in 41%. 
Baseline comorbidities included CHF (100%), CAD (84%), cardiomyopathy (51%), and previous cardiac surgery (67%). At baseline 90% of patients 
were in NYHA Class III/IV. Mean predicted surgical mortality (STS risk calculated or surgeon estimated) was 18% ± 8%. Actual 30 day mortality 
was 8%. Survival at 5 years was 44%. MR reduction remained durable with 70% of surviving patients experiencing MR reduction to ≤2+ at 5 years. 
Left ventricular end-diastolic volume (LVEDV) and LV end systolic volume (LVESV) showed clinically meaningful reduction sustained through 5 
years (LVEDV: 172 ± 52 ml, 138 ± 51 ml; LVESV: 81 ± 40 ml, 71 ± 39 ml). At 5 years a majority of surviving patients (83%) experienced reduced 
symptoms (NYHA Class I/II).
conclusion: The EVEREST II HRR currently has the longest clinical follow-up of high surgical risk patients post transcatheter MR reduction. 
The MitraClip procedure resulted in clinically meaningful and durable improvements in MR severity, significant improvements in LV remodeling, 
quality of life measures, and a significant reduction in re-hospitalization for CHF in these patients. Together, these results demonstrate durability of 
effectiveness outcomes through 5 years.
